No evidence for a large difference in ALS frequency in populations of African and European origin: A population based study in inner city London
Por:
Rojas-Garcia R., Scott K.M., Roche J.C., Scotton W., Martin N., Janssen A., Goldstein L.H., Nigel Leigh P., Ellis C.M., Shaw C.E., Al-Chalabi A.
Publicada:
1 ene 2012
Resumen:
Previous studies have suggested a lower incidence of ALS in people of African origin. We used a population based register in an urban setting from inner city London postcodes where there is a large population of people of African ancestry to compare the frequency of ALS in people of European and African origin. Population statistics stratified by age, gender and ethnicity were obtained from the 2001 census. Incidence and prevalence were calculated in each ethnic group. Results showed that in a population of 683,194, of which 22% were of African ancestry, 88 individuals with ALS were identified over a seven-year period, including 14 people with African ancestry. The adjusted incidence in people of African ancestry was 1.35 per 100,000 person-years (95% CI 0.722.3) and in those of European ancestry 1.97 per 100,000 person-years (95% CI 1.552.48). In conclusion, in this small population based study we could not detect a difference in rates of ALS between people of African ancestry and those of European ancestry. © 2012 Informa Healthcare.
Filiaciones:
Rojas-Garcia R.:
Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autnoma de Barcelona, Barcelona, Spain
Centro de Investigacin Biomédica en Red de Neurodegeneracin (CIBERNED), Spain
King's College London, MRC Centre for Neurodegeneration Research, Department of Clinical Neuroscience, London SE5 8AF, United Kingdom
Scott K.M.:
King's College London, MRC Centre for Neurodegeneration Research, Department of Clinical Neuroscience, London SE5 8AF, United Kingdom
Roche J.C.:
King's College London, MRC Centre for Neurodegeneration Research, Department of Clinical Neuroscience, London SE5 8AF, United Kingdom
Department of Neurology, Miguel Servet University Hospital, Zaragoza, Spain
Scotton W.:
King's College London School of Medicine, London, United Kingdom
Martin N.:
King's College London, MRC Centre for Neurodegeneration Research, Department of Psychology, London, United Kingdom
Janssen A.:
King's College London, MRC Centre for Neurodegeneration Research, Department of Psychology, London, United Kingdom
Goldstein L.H.:
King's College London, MRC Centre for Neurodegeneration Research, Department of Psychology, London, United Kingdom
Nigel Leigh P.:
King's College London, MRC Centre for Neurodegeneration Research, Department of Clinical Neuroscience, London SE5 8AF, United Kingdom
Brighton and Sussex Medical School, Trafford Centre for Biomedical Research, University of Sussex, Sussex, United Kingdom
Ellis C.M.:
Motor Nerve Clinic, Academic Neurosciences Centre, King's College Hospital, London, United Kingdom
Shaw C.E.:
King's College London, MRC Centre for Neurodegeneration Research, Department of Clinical Neuroscience, London SE5 8AF, United Kingdom
Al-Chalabi A.:
King's College London, MRC Centre for Neurodegeneration Research, Department of Clinical Neuroscience, London SE5 8AF, United Kingdom
|